PMID- 24557341
OWN - NLM
STAT- MEDLINE
DCOM- 20140902
LR  - 20210102
IS  - 1421-9662 (Electronic)
IS  - 0001-5792 (Linking)
VI  - 132
IP  - 1
DP  - 2014
TI  - HLA-G expression as a prognostic indicator in B-cell chronic lymphocytic 
      leukemia.
PG  - 53-8
LID - 10.1159/000353757 [doi]
AB  - BACKGROUND: The expression of human leukocyte antigen (HLA)-G was studied in 
      certain malignancies and its role in escaping from immunosurveillance in cancers 
      was proposed since HLA-G is a non-conventional HLA class I molecule that protects 
      the fetus from immunorecognition during pregnancy. Some particles involved in the 
      regulation of an immune system might represent prognostic value for B-cell 
      chronic lymphocytic leukemia (B-CLL). The identification of novel prognostic 
      factors in B-CLL may help define patient subgroups that may benefit from early 
      therapeutic intervention. OBJECTIVE: To evaluate the prognostic significance of 
      HLA-G expression in B-CLL patients and its relationship with other 
      well-established prognostic markers. METHODOLOGY: Thirty B-CLL patients diagnosed 
      by clinical, morphological and immunophenotyping criteria were studied for HLA-G 
      expression by flow cytometry. The relationship between HLA-G expression and some 
      known prognostic markers was evaluated. RESULTS: HLA-G was expressed in 36.7% of 
      CLL patients at diagnosis, with a mean expression level of 35.31 +/- 12.35%. A 
      significant association between HLA-G expression and common prognostic markers of 
      progressive disease was detected. The group of patients with positive HLA-G 
      expression showed significantly higher absolute lymphocyte counts and serum 
      levels of LDH and beta2-microglobulin, lower platelet counts, positive CD38 
      expression and advanced stages of Binet clinical staging. CONCLUSION: The present 
      study demonstrated that HLA-G expression correlates with prognostic markers of a 
      poor B-CLL outcome, mainly Binet clinical staging and CD38 expression by B-CLL 
      cells, which indicates that this parameter may play a role as an important 
      prognosticator of disease progression and consequently targeted therapy in B-CLL.
CI  - (c) 2014 S. Karger AG, Basel.
FAU - Attia, Mohamed A
AU  - Attia MA
AD  - Department of Clinical Pathology, Tanta University, Faculty of Medicine, Tanta, 
      Egypt.
FAU - Nosair, Nahla A
AU  - Nosair NA
FAU - Gawally, Amro
AU  - Gawally A
FAU - Elnagar, Gamal
AU  - Elnagar G
FAU - Elshafey, Eid M
AU  - Elshafey EM
LA  - eng
PT  - Journal Article
DEP - 20140215
PL  - Switzerland
TA  - Acta Haematol
JT  - Acta haematologica
JID - 0141053
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (HLA-G Antigens)
RN  - 0 (Membrane Glycoproteins)
RN  - EC 3.2.2.5 (CD38 protein, human)
RN  - EC 3.2.2.6 (ADP-ribosyl Cyclase 1)
SB  - IM
MH  - ADP-ribosyl Cyclase 1/blood
MH  - Aged
MH  - Biomarkers, Tumor/blood/immunology
MH  - Cohort Studies
MH  - Disease Progression
MH  - Female
MH  - Flow Cytometry
MH  - HLA-G Antigens/*blood
MH  - Humans
MH  - Immunophenotyping
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*blood/*immunology
MH  - Male
MH  - Membrane Glycoproteins/blood
MH  - Middle Aged
MH  - Prognosis
EDAT- 2014/02/22 06:00
MHDA- 2014/09/03 06:00
CRDT- 2014/02/22 06:00
PHST- 2013/01/31 00:00 [received]
PHST- 2013/06/11 00:00 [accepted]
PHST- 2014/02/22 06:00 [entrez]
PHST- 2014/02/22 06:00 [pubmed]
PHST- 2014/09/03 06:00 [medline]
AID - 000353757 [pii]
AID - 10.1159/000353757 [doi]
PST - ppublish
SO  - Acta Haematol. 2014;132(1):53-8. doi: 10.1159/000353757. Epub 2014 Feb 15.